Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated
The FDA-approved prescribing information for both semaglutide and tirzepatide specifically notes that they delay gastric emptying, which contributes to reduced appetite and caloric intake
This helps avoid B12 deficiency and ensures the best care for patients
Taking GLP-1 medications (even in small doses), especially when attempting to follow a fasting protocol without guidance, can increase the risk of unwanted side effects, nutrient deficiencies, or metabolic complications if you arent prescribed the proper dose and monitored during your treatment
Then comes the brain fog, that strange mental cloud wherein thinking feels very slow, words dont come easily, and even the smallest of decisions feel really exhausting
, ,